trending Market Intelligence /marketintelligence/en/news-insights/trending/Nsw3t541ANkC8ht-QMCX0Q2 content esgSubNav
In This List

XBiotech's bowel cancer treatment passes phase 3 trial

Blog

Commercial Banking: June 22nd Edition

Blog

Understanding Loss Given Default A Review of Three Approaches

Blog

Commercial Banking Newsletter June Edition - 2022

Blog

Insight Weekly: US recession outlook; mortgage activity slowdown; climate disclosure push


XBiotech's bowel cancer treatment passes phase 3 trial

XBiotech Inc. reported positive results from a phase 3 study evaluating its Hutruo antibody therapy as a potential treatment of advanced colorectal cancer, also known as bowel cancer and colon cancer.

According to the results, 40% of the patients who received the treatment achieved the main goal of reduced disease progression, as measured by the combination of patient-reported symptoms and radiography. This was nearly double compared to patients who received placebo.

Further, patients who achieved the primary endpoint demonstrated substantially improved survival outcomes, with a median survival of 11.7 months compared to the 5.7 months for those who did not.